Antiviral Activity and In Vitro Mutation Development Pathways of MK-6186, a Novel Nonnucleoside Reverse Transcriptase InhibitorMEIQING LU; FELOCK, Peter J; WILLIAMS, Theresa M et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 6, pp 3324-3335, issn 0066-4804, 12 p.Article

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4MARGOT, Nicolas A; HLUHANICH, Rebecca M; JONES, Gregg S et al.Antiviral research. 2012, Vol 93, Num 2, pp 288-296, issn 0166-3542, 9 p.Article

Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs)ZHIJIAN ZHAO; WOLKENBERG, Scott E; PRASAD, Sridar G et al.Bioorganic & medicinal chemistry letters (Print). 2008, Vol 18, Num 2, pp 554-559, issn 0960-894X, 6 p.Article

Automated high-throughput purification of antibody fragments to facilitate evaluation in functional and kinetic based assaysBIN SU; HRIN, Renee; HARVEY, Barrett R et al.Journal of immunological methods. 2007, Vol 322, Num 1-2, pp 94-103, issn 0022-1759, 10 p.Article

Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovirMARCHAND, Bruno; WHITE, Kirsten L; LY, John K et al.Antimicrobial agents and chemotherapy. 2007, Vol 51, Num 8, pp 2911-2919, issn 0066-4804, 9 p.Article

Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudineHAVLIR, Diane V; KOELSCH, Kersten K; STRAIN, Matthew C et al.The Journal of infectious diseases. 2005, Vol 191, Num 7, pp 1164-1168, issn 0022-1899, 5 p.Article

Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitroDELANEY, William E; HUILING YANG; MILLER, Michael D et al.Antimicrobial agents and chemotherapy. 2004, Vol 48, Num 10, pp 3702-3710, issn 0066-4804, 9 p.Article

Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tailWYMA, Donald J; JIYANG JIANG; JIONG SHI et al.Journal of virology. 2004, Vol 78, Num 7, pp 3429-3435, issn 0022-538X, 7 p.Article

Syntheses and biological evaluation of 5-(piperidin-1-yl)-3-phenyl-dentylsulfones as CCR5 antagonistsSHANKARAN, K; DONNELLY, Karla L; GOULD, Sandra L et al.Bioorganic & medicinal chemistry letters (Print). 2004, Vol 14, Num 13, pp 3589-3593, issn 0960-894X, 5 p.Article

Synthesis and biological evaluation of 5R- and 5S-methyl substituted D- and L-configuration 1,3-dioxolane nucleoside analogsBERA, Sanjib; MALIK, Leila; SCHLEIF, William A et al.Bioorganic & medicinal chemistry. 2004, Vol 12, Num 23, pp 6237-6247, issn 0968-0896, 11 p.Article

Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind studySCHOOLEY, Robert T; RUANE, Peter; MYERS, Robert A et al.AIDS (London). 2002, Vol 16, Num 9, pp 1257-1263, issn 0269-9370Article

Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failureLI, Jonathan Z; PAREDES, Roger; RIBAUDO, Heather J et al.AIDS (London). 2012, Vol 26, Num 2, pp 185-192, issn 0269-9370, 8 p.Article

The HIV-1 Reverse Transcriptase MI841 Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral FitnessKULKARNI, Rima; BABAOGLU, Kerim; LANSDON, Eric B et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 59, Num 1, pp 47-54, issn 1525-4135, 8 p.Article

Switching between raltegravir resistance pathways analyzed by deep sequencingMUKHERJEE, Rithun; JENSEN, Shane T; MALE, Frances et al.AIDS (London). 2011, Vol 25, Num 16, pp 1951-1959, issn 0269-9370, 9 p.Article

Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffoldWILLIAMS, Peter D; STAAS, Donnette D; ECTO, Linda T et al.Bioorganic & medicinal chemistry letters (Print). 2010, Vol 20, Num 22, pp 6754-6757, issn 0960-894X, 4 p.Article

10-Hydroxy-7,8-dihydropyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-1,9(2H,6H)-diones : Potent, orally bioavailable HIV-1 integrase strand-transfer inhibitors with activity against integrase mutantsWISCOUNT, Catherine M; WILLIAMS, Peter D; VACCA, Joseph P et al.Bioorganic & medicinal chemistry letters (Print). 2008, Vol 18, Num 16, pp 4581-4583, issn 0960-894X, 3 p.Article

Raltegravir with Optimized Background Therapy for Resistant HIV-1 InfectionSTEIGBIGEL, Roy T; COOPER, David A; KATLAMA, Christine et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 339-354, issn 0028-4793, 16 p.Article

Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosineSVAROVSKAIA, Evguenia S; MARGOT, Nicolas A; BAE, Andrew S et al.Journal of acquired immune deficiency syndromes (1999). 2007, Vol 46, Num 2, pp 174-180, issn 1525-4135, 7 p.Article

The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65R+M184VLY, John K; MARGOT, Nicolas A; MACARTHUR, Holly L et al.Antiviral chemistry & chemotherapy. 2007, Vol 18, Num 6, pp 307-316, issn 0956-3202, 10 p.Article

The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutationsWHITE, Kirsten L; CHEN, James M; FENG, Joy Y et al.Antiviral therapy (London). 2006, Vol 11, Num 2, pp 155-163, issn 1359-6535, 9 p.Article

Multicode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samplesSVAROVSKAIA, Evguenia S; MOSER, Michael J; BAE, Andrew S et al.Journal of clinical microbiology (Print). 2006, Vol 44, Num 11, pp 4237-4241, issn 0095-1137, 5 p.Article

Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutationWEBER, Jan; CHAKRABORTY, Bikram; WEBEROVA, Jitka et al.Journal of clinical microbiology (Print). 2005, Vol 43, Num 3, pp 1395-1400, issn 0095-1137, 6 p.Article

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virusDORE, Gregory J; COOPER, David A; POZNIAK, Anton L et al.The Journal of infectious diseases. 2004, Vol 189, Num 7, pp 1185-1192, issn 0022-1899, 8 p.Article

Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretrovkal-experienced patientsMILLER, Michael D; MARGOT, Nicolas; BIAO LU et al.The Journal of infectious diseases. 2004, Vol 189, Num 5, pp 837-846, issn 0022-1899, 10 p.Article

Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: Genotypic, phenotypic, and rebound analysesMARGOT, Nicolas A; ISAACSON, Erica; MCGOWAN, Lan et al.Journal of acquired immune deficiency syndromes (1999). 2003, Vol 33, Num 1, pp 15-21, issn 1525-4135, 7 p.Article